Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nanocort in active rheumatoid arthritis flares
NCT02534896Phase 3Terminated
- Sponsor
- Sun Pharma
- Start
- Nov 2015
- Primary completion
- Mar 2018
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial of liposomal prednisolone in rheumatoid arthritis (RA) (3 arms), sponsored by Sun Pharma. Primary endpoint: Good/Moderate European League Against Rheumatism Responders at 1 week. Started Nov 2015; status: terminated.
02
Drugs
liposomal prednisolone
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT02534896.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02534896.